Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


St Jude modifies HF (heart failure) device study:

This article was originally published in Clinica

Executive Summary

The US FDA has given St Jude Medical permission to reduce the required sample size in a trial of its cardiac resynchronisation device for treating heart failure (HF) patients who are also at risk of dangerously fast heart rhythms. The study, called RHYTHM, will now require six-month follow-up data on a minimum of 126 patients implanted with St Jude's Epic HF Model V-338 ICD, as opposed to 276 patients. The St Paul, Minnesota firm said it expected to complete the enrolment phase of study in early 2003 and to receive US regulatory approval of the device in early 2004.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts